Literature DB >> 11495176

Cognitive-behavioral treatment for depression in smoking cessation.

R A Brown1, C W Kahler, R Niaura, D B Abrams, S D Sales, S E Ramsey, M G Goldstein, E S Burgess, I W Miller.   

Abstract

Cigarette smokers with past major depressive disorder (MDD) received 8 group sessions of standard, cognitive-behavioral smoking cessation treatment (ST; n = 93) or standard, cognitive-behavioral smokiig cessation treatment plus cognitive-behavioral treatment for depression (CBT-D; n = 86). Although abstinence rates were high in both conditions (ST, 24.7%; CBT-D, 32.5%, at 1 year) for these nonpharmacological treatments, no main effect of treatment was found. However, secondary analyses revealed significant interactions between treatment condition and both recurrent depression history and heavy smoking ( > or =25 cigarettes a day) at baseline. Smokers with recurrent MDD and heavy smokers who received CBT-D were significantly more likely to be abstinent than those receiving ST (odds ratios = 2.3 and 2.6, respectively). Results suggest that CBT-D provides specific benefits for some, but not all, smokers with a history of MDD.

Entities:  

Mesh:

Year:  2001        PMID: 11495176      PMCID: PMC1832078          DOI: 10.1037//0022-006x.69.3.471

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  30 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Major depression following smoking cessation.

Authors:  L S Covey; A H Glassman; F Stetner
Journal:  Am J Psychiatry       Date:  1997-02       Impact factor: 18.112

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Effects of nicotine fading and relapse prevention on smoking cessation.

Authors:  R A Brown; E Lichtenstein; K O McIntyre; J Harrington-Kostur
Journal:  J Consult Clin Psychol       Date:  1984-04

5.  A psychoeducational approach to the treatment of depression: comparison of group, individual, and minimal contact procedures.

Authors:  R A Brown; P M Lewinsohn
Journal:  J Consult Clin Psychol       Date:  1984-10

6.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene.

Authors:  C Lerman; N Caporaso; D Main; J Audrain; N R Boyd; E D Bowman; P G Shields
Journal:  Health Psychol       Date:  1998-01       Impact factor: 4.267

8.  Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study.

Authors:  S M Hall; R F Muñoz; V I Reus; K L Sees; C Duncan; G L Humfleet; D T Hartz
Journal:  J Consult Clin Psychol       Date:  1996-10

9.  Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement.

Authors:  T Kinnunen; K Doherty; F S Militello; A J Garvey
Journal:  J Consult Clin Psychol       Date:  1996-08

10.  Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.

Authors:  S M Hall; V I Reus; R F Muñoz; K L Sees; G Humfleet; D T Hartz; S Frederick; E Triffleman
Journal:  Arch Gen Psychiatry       Date:  1998-08
View more
  77 in total

1.  Dysphoria and smoking among treatment seeking smokers: the role of smoking-related inflexibility/avoidance.

Authors:  Julia D Buckner; Samantha G Farris; Michael J Zvolensky; Sonia M Shah; Adam M Leventhal; Jennifer A Minnix; Norman B Schmidt
Journal:  Am J Drug Alcohol Abuse       Date:  2014-11-14       Impact factor: 3.829

2.  Positive Psychotherapy for Smoking Cessation: Treatment Development, Feasibility and Preliminary Results.

Authors:  Christopher W Kahler; Nichea S Spillane; Anne Day; Elise Clerkin; Acacia Parks; Adam M Leventhal; Richard A Brown
Journal:  J Posit Psychol       Date:  2014-01-01

Review 3.  Applying the tripartite model of anxiety and depression to cigarette smoking: an integrative review.

Authors:  Katherine J Ameringer; Adam M Leventhal
Journal:  Nicotine Tob Res       Date:  2010-10-29       Impact factor: 4.244

4.  Personality disorders and the 3-year course of alcohol, drug, and nicotine use disorders.

Authors:  Deborah Hasin; Miriam C Fenton; Andrew Skodol; Robert Krueger; Katherine Keyes; Timothy Geier; Eliana Greenstein; Carlos Blanco; Bridget Grant
Journal:  Arch Gen Psychiatry       Date:  2011-11

5.  Depression vulnerability moderates the effects of cognitive behavior therapy in a randomized controlled trial for smoking cessation.

Authors:  Heather Schloss Kapson; David A F Haaga
Journal:  Behav Ther       Date:  2010-05-05

Review 6.  Distress tolerance and early smoking lapse.

Authors:  Richard A Brown; C W Lejuez; Christopher W Kahler; David R Strong; Michael J Zvolensky
Journal:  Clin Psychol Rev       Date:  2005-09

7.  Addressing nicotine dependence in psychodynamic psychotherapy: perspectives from residency training.

Authors:  Judith J Prochaska; Sebastien C Fromont; Peter Banys; Stuart J Eisendrath; Mardi J Horowitz; Marc H Jacobs; Sharon M Hall
Journal:  Acad Psychiatry       Date:  2007 Jan-Feb

8.  Bupropion and cognitive-behavioral treatment for depression in smoking cessation.

Authors:  Richard A Brown; Raymond Niaura; Elizabeth E Lloyd-Richardson; David R Strong; Christopher W Kahler; Ana M Abrantes; David Abrams; Ivan W Miller
Journal:  Nicotine Tob Res       Date:  2007-07       Impact factor: 4.244

9.  Anhedonia, depressed mood, and smoking cessation outcome.

Authors:  Adam M Leventhal; Megan E Piper; Sandra J Japuntich; Timothy B Baker; Jessica W Cook
Journal:  J Consult Clin Psychol       Date:  2013-11-11

10.  Hostility, cigarette smoking, and responses to a lab-based social stressor.

Authors:  Christopher W Kahler; Adam M Leventhal; Suzanne M Colby; Chad J Gwaltney; Thomas W Kamarck; Peter M Monti
Journal:  Exp Clin Psychopharmacol       Date:  2009-12       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.